Values as of: 2024-11-03
COMMON STOCK | Biotechnology |
Last Closing
USD 15.5Change
0.00 (0.00)%Market Cap
USD 1.58BVolume
0.81MAnalyst Target
USD 38.67Verdict
Verdict
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
Company Website : https://www.arcusbio.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| BHVN | Biohaven Pharmaceutical Holdin.. |
N/A |
USD 5.14B |
| NUVB | Nuvation Bio Inc |
N/A |
USD 0.74B |
| DNA | Ginkgo Bioworks Holdings |
N/A |
USD 0.50B |
| ANRO | Alto Neuroscience, Inc. |
N/A |
USD 0.37B |
| ADCT | ADC Therapeutics SA |
N/A |
USD 0.29B |
| CYBN | Cybin Inc |
N/A |
USD 0.21B |
| ANVS | Annovis Bio Inc |
N/A |
USD 0.12B |
| ARMP | Armata Pharmaceuticals Inc |
N/A |
USD 0.09B |
| PLX | Protalix Biotherapeutics Inc |
N/A |
USD 0.08B |
| OSTX | OS Therapies Incorporated |
N/A |
USD 0.07B |
N/A
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -18.85% | 24% | F | 19% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -18.85% | 24% | F | 21% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -5.31% | 21% | F | 21% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -5.31% | 21% | F | 24% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 85.41% | 81% | B- | 82% | B | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 85.41% | 81% | B- | 82% | B | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 13.83% | 67% | D+ | 75% | C | ||
| Dividend Return | 13.83% | 67% | D+ | 71% | C- | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 73.07% | 61% | D- | 12% | F | ||
| Risk Adjusted Return | 18.93% | 79% | B- | 37% | F | ||
| Market Capitalization | 1.58B | 96% | N/A | 64% | D | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
